16.1 million American adults, or about 6.7% of the adult U.S. population, are affected by major depressive disorder.
Worldwide, over 300 million individuals suffer from depression. Despite the availability of over 25 FDA approved drugs for depression, a significant portion of patients experience poor outcomes.
Only 35% of patients on SSRIs experience full remission of symptoms. The rest experience temporary and/or partial relief. More so, about 30% of all patients with depression don’t respond adequately to the available treatments. As many as 5 million people in the U.S. have treatment-resistant depression.
Selecting an effective medication is a taxing trial-and-error process. Impact of a medication can take weeks to appear. Patients with postpartum depressive disorder have no effective solutions, as most don’t want to take currently available drugs.
Scientists are gaining a more nuanced picture of depression. It is not a monolithic disease, but rather, dozens of distinct maladies each with multiple contributors.
uMETHOD is currently developing a combination therapy approach to advance the care of patients with major depressive disorder. We intend to provide hope to the 65% of patients not adequately served by the standard-of-care.
Patients and physicians can sign up below to receive updates on our progress.
We value your privacy. Your personal information is kept confidential and not sold to third parties. It is only used for communications you request related to the services provided by uMETHOD.